Oncology Biosimilars Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : May-2020 | List of Tables : 29 | List of Figures : 75 | No. of Pages : 170 | Report Code : FACT4800MR | Format :

Global Oncology Biosimilars Market Overview:

Cancer is attributed as the second leading cause of fatalities across the world. According to the World Health Organization, an estimated 9.6 million deaths occurred in 2018. Naturally, pharmaceutical companies have boosted cancer treatment drugs production to cater to such a large pool of patients. Since blockbuster biologic drugs are quite expensive, the stage is set for the entry of biosimilar and generic drugs. Based on these trends, the oncology biosimilars market is looking at a bright future ahead expanding at a stellar CAGR of 29.4% by 2025 end.

The ongoing COVID-19 pandemic, however, is anticipated to inhibit progress in the short-run. Supply shortages, owing to nationwide lockdowns across emerging economies, are anticipated to occur. Likewise, the shifted focus of healthcare providers to care for COVID-19 patients are poised to delay evaluation and uptake of biosimilar drugs. This is because healthcare providers would prefer to stick to the status quo therapy options and proceed with existing drugs. Moreover, delays in biosimilar clinical trials are further anticipated to limit growth prospects in the near-term. However, post-COVID-19, the global oncology biosimilars market shall experience a resurgence.

Global Oncology Biosimilars Market Analysis by Disease Indication:

The blood cancers segment is projected to expand the fastest, at a whopping 33.0% CAGR during the forecast period. This is mostly attributed to a rising number of novel drugs in the pipeline of key manufacturers. The blood cancers segment is anticipated to capture more than 1/5th of the total oncology biosimilars market.

However, the neutropenia segment is poised to dominate the global oncological biosimilars market, capturing more than half of the total market share. Expiration of patented blockbuster biologics has paved way for increased usage of biosimilar products in the segment. In 2018, the FDA approved the use of filgrastim-aafi manufactured by Pfizer, for treating neutropenia among patients who have undergone blood cancer treatment. The neutropenia segment is anticipated to expand at a dexterous CAGR of 29.6%.

global oncolology biosimilars market size growth forecast by disease indication

Get the latest COVID-19 impact insights on the oncology biosimilars market, by asking an analyst here

Global Oncology Biosimilars Market Regional Insights:

The Asia-Pacific oncology biosimilars market is set to register aggrandizing growth, expanding at a CAGR of 30.7%, thus reaching a position of market dominance. The Asia-Pacific market is poised to capture more than one-third of the overall market. This impressive growth trajectory is attributed to active collaboration within market giants to expand profit pools. For instance, in 2016, Dr. Reddy’s Laboratories collaborated with TR-Pharm to commercialize the former’s three biosimilars in Turkey.

global oncolology biosimilars market growth forecast by region

Access our cutting-edge regional insights on the oncology biosimilars market by requesting for a report sample here

North America presents equally lucrative growth opportunities. Burgeoning investment in research and development to develop pipeline portfolios is a key growth driver of the region. Biocon, a leading Indian pharmaceutical company, owns three pipeline biosimilars in the oncology segment. Apotex Inc. has five biosimilars in its pipeline. Together, the companies have introduced these drugs into the market. The North American oncology biosimilars market is set to expand at a CAGR of 32.0%, capturing over a quarter of the market.

Global Oncology Biosimilars Market Companies’ Strategies

The global oncology biosimilars market consists of the following market players: Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh. This makes it a highly consolidated market. Collectively, these market players account for more than 70% of the market share. In order to broad based their market footprints, these companies rely heavily on strengthening their product distribution networks through active collaborations.

Biocon, for instance, announced an exclusive global collaboration with Sandoz on next-generation biosimilars in 2018. Likewise, Dr. Reddy’s collaborated with TR Pharm to launch three biosimilars in Turkey in 2016. Other prominent market players in the global oncology biosimilars market include Pfizer, Inc., Celltrion, Inc., Sandoz International GmBh, STADA Arzneimittel AG and Apotex, Inc. to name a few.

COVID-19’s Impact on Oncology Biosimilars Market:

The ongoing COVID-19 pandemic has brought the world to a standstill. With business operations getting suspended, industries are facing supply chain disruptions and a subsequent demand-supply gap. With regard to oncology biosimilars, the market is anticipated to register a decline in the short-run. This is attributed to shifting priorities of healthcare providers towards addressing patients with acute COVID-19 infections. Delays in clinical trials are anticipated, owing to this, which will eventually delay product launches. Fortunately, providers are looking for options to compensate for the extra expenses they are incurring at the present moment. It will become more important than ever for biosimilars to deliver on their promise of bringing savings to the healthcare system.

Analyst’s Viewpoint:

The global oncology biosimilars market is set to embark on a positive growth path throughout the forecast period. Blockbuster generic drugs have now reached a cliffhanger, anticipated to soon phase out. This is providing immense opportunities for companies operating in this market to expand their product portfolios. Moreover, lucrative opportunities exist in the Asia-Pacific, owing to presence of important market players as well as increasing cancer cases attributed to sedentary lifestyles.

Global Oncology Biosimilars Market: Report Scope:

The recent study on oncology biosimilars published by Fact.MR incorporates a 5-year forecast period from 2020 to 2025 and explicates on vital dynamics such as the key drivers, opportunities and restraints for the market. The report analyses the market based on the following segments: drug class, disease indication and distribution channel. Each segment includes a detailed analysis in terms of market share, revenue and overall growth.

A section on regional analysis has been included based on the following four geographies: North America, Europe, Asia-Pacific and Rest of the World. Each region has been analyzed based on the aforementioned segments.

Global Oncology Biosimilars Market- Scope of the Report

The recent study by Fact.MR on the global oncology biosimilars market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends currently determining the growth of the market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the production of oncology biosimilars products. The study also provides dynamics responsible for influencing the future status of the global oncology biosimilars market over the forecast period.

A detailed assessment of the global oncology biosimilars market’s value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global oncology biosimilars market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Oncology Biosimilars Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global oncology biosimilars market across the globe.

A comprehensive estimate on the global oncology biosimilars market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of global oncology biosimilars market during the forecast period.

Global Oncology biosimilars Market Segmentation

Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel and region.

Drug Class

Disease Indication

Distribution Channel

Region

G-CSF

Breast Cancer

Hospital Pharmacy

North America

Monoclonal Antibody

Non-Small Cell Lung Cancer

Retail Pharmacy

Europe

Hematopoietic Agents

Colorectal Cancer

Online Pharmacy

Asia Pacific

 

Neutropenia

 

Rest of the World

 

Blood Cancer:

Leukemia:

Myeloid Leukemia

Chronic Lymphocytic Leukemia (CLL)

Others

 

Non-Hodgkin Lymphoma

 

 

 

Others

 

 

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Oncology Biosimilars Market: Analysis on Market Size Evaluation

The global oncology biosimilars market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for global oncology biosimilars market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent global oncology biosimilars market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Oncology Biosimilars Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global oncology biosimilars report, which have helped deliver projections on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global oncology biosimilars market during the forecast period.

Country-specific valuation on demand for global oncology biosimilars has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Global Oncology Biosimilars Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global oncology biosimilars products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global oncology biosimilars products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global oncology biosimilars market. Prominent manufacturers with established market presence in the global oncology biosimilars market are Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh.

Section 01. Preface

    1.1. Market Definition and Scope

    1.2. Research Highlights

Section 02. Assumptions and Research Methodology

    2.1. Assumptions & Acronyms Used

    2.2. Research Methodology

Section 03. Executive Summary: Global Oncology Biosimilar Market

    3.1. Executive Summary

    3.2. Market Opportunity Map

    3.3. Market Overview

    3.4. Key Industry Developments

    3.5. Global Oncology Biosimilar Market Size (US$ Mn) Forecast, 2020–2025

    3.6. Global Oncology Biosimilar Market Outlook

Section 04. Market Dynamics

    4.1. Drivers

    4.2. Restraints

    4.3. Opportunity

    4.4. Key Trends

Section 05. Porter’s Five Force Analysis

Section 06. Oncology Biosimilars: Key Molecules

Section 07. Biosimilars Market Snapshot

Section 08. Cancer Statistics

Section 09. Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class

    9.1. Introduction & Definition

    9.2. Key Findings 

    9.3. Global Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025

    9.4. Market Attractiveness by Drug Class 

    9.5. Global Oncology Biosimilars Market Forecast, by Drug Class, 2020-2025

        9.5.1. G-CSF

        9.5.2. Monoclonal Antibody

        9.5.3. Hematopoietic Agents

    9.6. Global Oncology Biosimilars Market Analysis, by Drug Class, 2020-2025

    9.7. Key Trends

Section 10. Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication 

    10.1. Introduction & Definition

    10.2. Key Findings 

    10.3. Global Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025

    10.4. Market Attractiveness By Disease Indication

    10.5. Global Oncology Biosimilars Market Forecast, by Disease Indication, 2020-2025

        10.5.1. Breast Cancer

        10.5.2. Non-Small Cell lung Cancer

        10.5.3. Blood Cancer

            10.5.3.1. Leukemia

                10.5.3.1.1. Myeloid Leukemia

                10.5.3.1.2. Chronic Lymphocytic Leukemia

                10.5.3.1.3. Others

            10.5.3.2. Non-Hodgkin Lymphoma

        10.5.4. Colorectal Cancer

        10.5.5. Neutropenia

        10.5.6. Others

    10.6. Global Oncology Biosimilars Market Analysis, by Disease Indication, 2020-2025

    10.7. Key Trends

Section 11. Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel 

    11.1. Introduction & Definition

    11.2. Key Findings 

    11.3. Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025

    11.4. Market Attractiveness By Distribution Channel

    11.5. Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2020-2025

        11.5.1. Hospital Pharmacy

        11.5.2. Online Pharmacy

        11.5.3. Retail Pharmacy

    11.6. Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2020-2025

    11.7. Key Trends

Section 12. Global Oncology Biosimilars Market Analysis and Forecasts, By Region

    12.1. Global Market Scenario

    12.2. Global Oncology Biosimilars Market Value Share, by Region, 2020 and 2025

    12.3. Global Oncology Biosimilars Market Attractiveness, by Region, 2020–2025

    12.4. Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2020–2025

        12.4.1. North America 

        12.4.2. Europe 

        12.4.3. Asia Pacific 

        12.4.4. Rest of the World 

Section 13. North America Oncology Biosimilars Market Analysis and Forecast

    13.1. North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025

    13.2. North America Oncology Biosimilars Market Value Share, by Country, 2020 and 2025

    13.3. North America Oncology Biosimilars Market Attractiveness, by Country, 2020–2025

    13.4. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025

        13.4.1. U.S.

        13.4.2. Canada

    13.5. North America Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025

    13.6. North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025

    13.7. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025

        13.7.1. G-CSF

        13.7.2. Monoclonal Antibody

        13.7.3. Hematopoietic Agents

    13.8. North America Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025

    13.9. North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025

    13.10. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025

        13.10.1. Breast Cancer

        13.10.2. Non-Small Cell lung Cancer

        13.10.3. Blood Cancer

            13.10.3.1. Leukemia

                13.10.3.1.1. Myeloid Leukemia

                13.10.3.1.2. Chronic Lymphocytic Leukemia

                13.10.3.1.3. Others

            13.10.3.2. Non-Hodgkin Lymphoma

        13.10.4. Colorectal Cancer

        13.10.5. Neutropenia

        13.10.6. Others

    13.11. North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025

    13.12. North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025

    13.13. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025

        13.13.1. Hospital Pharmacy

        13.13.2. Online Pharmacy

        13.13.3. Retail Pharmacy

    13.14. Key Trends

Section 14. Europe Oncology Biosimilars Market Analysis and Forecast

    14.1. Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025

    14.2. Europe Oncology Biosimilars Market Value Share, by Country, 2020 and 2025

    14.3. Europe Oncology Biosimilars Market Attractiveness, by Country, 2020–2025

    14.4. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025

        14.4.1. U.K.

        14.4.2. Germany

        14.4.3. France

        14.4.4. Italy

        14.4.5. Russia

        14.4.6. Spain

        14.4.7. Rest of Europe

    14.5. Europe Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025

    14.6. Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025

    14.7. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025

        14.7.1. G-CSF

        14.7.2. Monoclonal Antibody

        14.7.3. Hematopoietic Agents

    14.8. Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025

    14.9. Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025

    14.10. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025

        14.10.1. Breast Cancer

        14.10.2. Non-Small Cell lung Cancer

        14.10.3. Blood Cancer

            14.10.3.1. Leukemia

                14.10.3.1.1. Myeloid Leukemia

                14.10.3.1.2. Chronic Lymphocytic Leukemia

                14.10.3.1.3. Others

            14.10.3.2. Non-Hodgkin Lymphoma

        14.10.4. Colorectal Cancer

        14.10.5. Neutropenia

        14.10.6. Others

    14.11. Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025

    14.12. Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025

    14.13. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025

        14.13.1. Hospital Pharmacy

        14.13.2. Online Pharmacy

        14.13.3. Retail Pharmacy

    14.14. Key Trends

Section 15. Asia Pacific Oncology Biosimilars Market Analysis and Forecast

    15.1. Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025

    15.2. Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2020 and 2025

    15.3. Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2020–2025

    15.4. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025

        15.4.1. China

        15.4.2. India

        15.4.3. Japan

        15.4.4. Australia & New Zealand

        15.4.5. Rest of Asia Pacific

    15.5. Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025

    15.6. Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025

    15.7. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025

        15.7.1. G-CSF

        15.7.2. Monoclonal Antibody

        15.7.3. Hematopoietic Agents

    15.8. Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025

    15.9. Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025

    15.10. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025

        15.10.1. Breast Cancer

        15.10.2. Non-Small Cell lung Cancer

        15.10.3. Blood Cancer

            15.10.3.1. Leukemia

                15.10.3.1.1. Myeloid Leukemia

                15.10.3.1.2. Chronic Lymphocytic Leukemia

                15.10.3.1.3. Others

            15.10.3.2. Non-Hodgkin Lymphoma

        15.10.4. Colorectal Cancer

        15.10.5. Neutropenia

        15.10.6. Others

    15.11. Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025

    15.12. Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025

    15.13. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025

        15.13.1. Hospital Pharmacy

        15.13.2. Online Pharmacy

        15.13.3. Retail Pharmacy

    15.14. Key Trends

Section 16. Rest of the World Oncology Biosimilars Market Analysis and Forecast

    16.1. Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025

    16.2. Rest of the World Oncology Biosimilars Market Value Share, by Country, 2020 and 2025

    16.3. Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2020–2025

    16.4. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025

        16.4.1. Mexico

        16.4.2. Brazil

        16.4.3. Rest of the World

    16.5. Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025

    16.6. Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025

    16.7. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025

        16.7.1. G-CSF

        16.7.2. Monoclonal Antibody

        16.7.3. Hematopoietic Agents

    16.8. Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025

    16.9. Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025

    16.10. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025

        16.10.1. Breast Cancer

        16.10.2. Non-Small Cell lung Cancer

        16.10.3. Blood Cancer

            16.10.3.1. Leukemia

                16.10.3.1.1. Myeloid Leukemia

                16.10.3.1.2. Chronic Lymphocytic Leukemia

                16.10.3.1.3. Others

            16.10.3.2. Non-Hodgkin Lymphoma

        16.10.4. Colorectal Cancer

        16.10.5. Neutropenia

        16.10.6. Others

    16.11. Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025

    16.12. Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025

    16.13. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025

        16.13.1. Hospital Pharmacy

        16.13.2. Online Pharmacy

        16.13.3. Retail Pharmacy

    16.14. Key Trends

Section 17. Competition Landscape

    17.1. Market Player – Competition Matrix (By Tier and Size of companies)

    17.2. Market Share Analysis By Company (2018)

Section 18. Company Profiles

    18.1. Sandoz International GmbH

        18.1.1. Company Details

        18.1.2. Business Overview

        18.1.3. Financial Overview

        18.1.4. Strategic Overview

        18.1.5. SWOT Analysis

    18.2. Pfizer, Inc.

        18.2.1. Company Details

        18.2.2. Business Overview

        18.2.3. Financial Overview

        18.2.4. Strategic Overview

        18.2.5. SWOT Analysis

    18.3. Celltrion Inc.

        18.3.1. Company Details

        18.3.2. Business Overview

        18.3.3. Financial Overview

        18.3.4. Strategic Overview

        18.3.5. SWOT Analysis

    18.4. Dr. Reddy’s Laboratories Ltd.

        18.4.1. Company Details

        18.4.2. Business Overview

        18.4.3. Financial Overview

        18.4.4. Strategic Overview

        18.4.5. SWOT Analysis

    18.5. Biocon

        18.5.1. Company Details

        18.5.2. Business Overview

        18.5.3. Financial Overview

        18.5.4. Strategic Overview

        18.5.5. SWOT Analysis

    18.6. Teva Pharmaceutical Industries Ltd.

        18.6.1. Company Details

        18.6.2. Business Overview

        18.6.3. Financial Overview

        18.6.4. Strategic Overview

        18.6.5. SWOT Analysis

    18.7. STADA Arzneimittel AG

        18.7.1. Company Details

        18.7.2. Business Overview

        18.7.3. Financial Overview

        18.7.4. Strategic Overview

        18.7.5. SWOT Analysis

    18.8. Apotex Inc. (Apobiologix)

        18.8.1. Company Details

        18.8.2. Business Overview

        18.8.3. Financial Overview

        18.8.4. Strategic Overview

        18.8.5. SWOT Analysis

    18.9. Intas Pharmaceuticals Ltd.

        18.9.1. Company Details

        18.9.2. Business Overview

        18.9.3. Financial Overview

        18.9.4. Strategic Overview

        18.9.5. SWOT Analysis

    18.10. BIOCAD

        18.10.1. Company Details

        18.10.2. Business Overview

        18.10.3. Financial Overview

        18.10.4. Strategic Overview

        18.10.5 SWOT Analysis

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Oncology Biosimilars Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025